Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 0.8 -9.09% -0.08
XBIO closed down 9.09 percent on Friday, May 17, 2019, on 1.49 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 21

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical XBIO trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -9.09%
180 Bearish Setup Bearish Swing Setup -9.09%
Volume Surge Other -9.09%
Lower Bollinger Band Walk Weakness -9.09%

Older signals for XBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Dialysis Chronic Kidney Disease Anemia Drug Therapies Refractory Acute Myeloid Leukemia Product Candidates Growth Factors
Is XBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.95
52 Week Low 0.8
Average Volume 69,426
200-Day Moving Average 2.2786
50-Day Moving Average 1.6464
20-Day Moving Average 1.3126
10-Day Moving Average 1.18
Average True Range 0.144
ADX 24.01
+DI 10.1023
-DI 33.9406
Chandelier Exit (Long, 3 ATRs ) 1.296
Chandelier Exit (Short, 3 ATRs ) 1.232
Upper Bollinger Band 1.7059
Lower Bollinger Band 0.9193
Percent B (%b) -0.15
BandWidth 59.926863
MACD Line -0.1852
MACD Signal Line -0.1478
MACD Histogram -0.0373
Fundamentals Value
Market Cap 6.98 Million
Num Shares 8.72 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 6.14
Price-to-Book 1.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.95
Resistance 3 (R3) 0.97 0.93 0.92
Resistance 2 (R2) 0.93 0.89 0.92 0.92
Resistance 1 (R1) 0.87 0.87 0.85 0.85 0.91
Pivot Point 0.83 0.83 0.82 0.82 0.83
Support 1 (S1) 0.77 0.80 0.75 0.75 0.69
Support 2 (S2) 0.73 0.77 0.73 0.68
Support 3 (S3) 0.67 0.73 0.68
Support 4 (S4) 0.65